Value added growth rate of pharmaceutical manufacturing vs Oncology novel active substance (NAS) launches (cumulative) in China

Value added growth rate of pharmaceutical manufacturing and Oncology novel active substance (NAS) launches (cumulative) in China, compared over time.

Change the pair

Compare different indicators

The series

Over time

China, spaced by time . Different units, drawn on separate scales and clipped to the years both series publish — earlier history stays on each indicator's own page. Read the values, not the heights.

Value added growth rate of pharmaceutical manufacturing

Unit: % · 2 observations

Line chart
Value added growth rate of pharmaceutical manufacturingValue added growth rate of pharmaceutical manufacturing. 2 observations from as of 31 Jul 2026 to July 2026, ranging from 2.8% to 5.3%. Latest value 2.8% (July 2026). % 0 1 2 3 4 5 6 2015 2017 2019 2021 2023 2025 5.3% 2.8%
Value added growth rate of pharmaceutical manufacturingValue added growth rate of pharmaceutical manufacturing. 2 observations from as of 31 Jul 2026 to July 2026, ranging from 2.8% to 5.3%. Latest value 2.8% (July 2026). % 0 2 4 6 2015 2017 2019 2021 2023 2025 5.3% 2.8%
Value added growth rate of pharmaceutical manufacturingValue added growth rate of pharmaceutical manufacturing. 2 observations from as of 31 Jul 2026 to July 2026, ranging from 2.8% to 5.3%. Latest value 2.8% (July 2026). % 0 2 4 6 2015 2017 2019 2021 2023 2025 5.3% 2.8%
View the underlying data
Value added growth rate of pharmaceutical manufacturing
Period Type Value
as of 31 Jul 2026 Actual 5.3%
July 2026 Actual 2.8%
Source: NBS China · CC BY 4.0 · Full series

Oncology novel active substance (NAS) launches (cumulative)

Unit: count · 2 observations

Line chart
Oncology novel active substance (NAS) launches (cumulative)Oncology novel active substance (NAS) launches (cumulative). 2 observations from 2015–2019 to 2020–2024, ranging from 37 to 84. Latest value 84 (2020–2024). 0 20 40 60 80 100 2015 2017 2019 2021 2023 2025 37 84
Oncology novel active substance (NAS) launches (cumulative)Oncology novel active substance (NAS) launches (cumulative). 2 observations from 2015–2019 to 2020–2024, ranging from 37 to 84. Latest value 84 (2020–2024). 0 30 60 90 2015 2017 2019 2021 2023 2025 37 84
Oncology novel active substance (NAS) launches (cumulative)Oncology novel active substance (NAS) launches (cumulative). 2 observations from 2015–2019 to 2020–2024, ranging from 37 to 84. Latest value 84 (2020–2024). 0 30 60 90 2015 2017 2019 2021 2023 2025 37 84
View the underlying data
Oncology novel active substance (NAS) launches (cumulative)
Period Type Value
2015–2019 Actual 37
2020–2024 Actual 84
Source: IQVIA · CC BY 4.0 · Full series

Provenance

Where these numbers come from

Value added growth rate of pharmaceutical manufacturing

Year-on-year percentage change in the real value added of the pharmaceutical manufacturing industry among industrial sectors.

2 observations in China · source organisations: NBS China

Oncology novel active substance (NAS) launches (cumulative)

Total number of oncology novel active substances launched over a stated multi-year period.

2 observations in China · source organisations: IQVIA

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related